Telaid Launches Integrated Security Strategies to Balance Retail Theft Prevention and Customer Experience
NORCROSS, Ga., June 16, 2025 (GLOBE NEWSWIRE) — Telaid , a trusted technology integrator, has rolled out its integrated security strategies aimed at helping retailers reduce theft while maintaining a positive customer experience. As retail crime continues to rise nationwide, the company's approach combines physical security infrastructure with intelligent technology and staff training to support retailers in adapting to evolving threats.
According to the National Retail Federation's (NRF) 2023 National Retail Security Survey, inventory shrink reached $112.1 billion in 2022, up from $93.9 billion the year before. More than 70% of retailers reported an increase in aggressive and violent organized retail crime (ORC). In response, many stores have resorted to visible deterrents such as locking up products or placing guards at entrances—measures that can create friction for everyday shoppers.
'You shouldn't need to find an associate just to buy a toothbrush,' s aid Steve Collins, Vice President of Business Development at Telaid. 'It's a friction point that erodes customer trust, especially when it's not balanced with thoughtful strategy.'
Telaid's integrated security strategies are designed to offer a more balanced alternative. The company provides end-to-end solutions that include network infrastructure, wireless capabilities, and physical security systems. These systems are layered with intelligent tools such as AI-powered video analytics, RFID tags, and self-locking shopping carts, which can detect and deter suspicious behavior without disrupting the shopping experience.
'When layered strategically, these technologies can reduce loss without turning stores into fortresses,' Collins said.
Integrated platforms are also helping retailers improve response times and make better-informed decisions. Telaid's unified systems bring together video surveillance, access control, electronic article surveillance (EAS), and analytics dashboards into a single interface. This enables asset protection teams to identify trends, track incidents, and coordinate responses more effectively.
'These systems don't just alert you to theft—they help identify when and where it's happening, how often, and under what circumstances,' said Collins. 'That data becomes actionable when you're trying to decide whether to invest in personnel, tech upgrades, or operational changes.'
The strategies also include design elements that limit the visibility of security features. To avoid making customers feel watched or distrusted, many retailers are choosing discreet surveillance options such as ceiling-mounted AI cameras, low-profile sensors, and intelligent shelving.
Training is another critical component of Telaid's strategy. The company works with retailers to train store associates not only on how to use the new technologies, but also how to identify threats, follow non-confrontational protocols, and maintain a safe environment.
According to the NRF, many retailers are implementing safety-first policies that discourage direct engagement with suspected offenders. The emphasis is on de-escalation and staff safety.
Decision-making in retail security is also becoming more localized. Telaid supports this shift by equipping district managers and local asset protection leaders with tools and data that allow for real-time responses tailored to local conditions.
'The stakes are too high. Retailers that blend smart technology with a customer-first mindset will be the ones that stay competitive as expectations change,' Collins added.
As retailers face increasing pressures from theft, evolving threats, and customer expectations, Telaid's integrated security strategies aim to provide a practical and scalable solution. The approach enables loss prevention efforts to become part of a retailer's overall strategy—supporting profitability, safety, and the shopping experience.
About Telaid
Telaid is a leading technology integrator specializing in the rapid deployment of IT infrastructure, physical security, and wireless solutions. With over 40 years of experience, Telaid helps enterprises in retail and other industries achieve operational efficiency and business resilience through turnkey technology deployment and support. The company delivers customized solutions that meet evolving business needs across hundreds of locations nationwide.
Contact Information:Name: Jill ZylstraWebsite: telaid.comCompany: Telaid
Email:[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
26 minutes ago
- The Hill
Collins looks to navigate Trump, funding landmines as 2026 looms
Sen. Susan Collins (R-Maine) is feeling the squeeze as she navigates a series of political landmines that put her at odds with President Trump and many of her own colleagues. Collins this summer voted 'no' on two of Trump's biggest priorities: the GOP's mammoth tax and spending bill and a measure to claw back money Congress had already appropriated. She also opposed several of the president's high-profile Cabinet nominees. Her vote on the rescissions measure only complicated her next difficult task: shepherding government funding legislation to Trump's desk as chair of the Senate Appropriations Committee — her longtime dream job that she finally secured earlier this year. And hovering in the background is next year's midterms, when she is expected to seek a sixth term in a seat Democrats are eyeing as a key pickup opportunity. 'Give me one senator who would trade her position,' said Sen. Markwayne Mullin (R-Okla.), a top ally of Senate Majority Leader John Thune (R-S.D.) and an Appropriations panel member. He answered his own question: 'None.' Collins has long been a one-of-one member in the conference, as the foremost centrist from a blue state that GOP leadership has had to juggle as part of a membership that has trended more MAGA throughout the years. But while that balance has always been tough, it has perhaps never been more difficult than it is right now. Collins is in the midst of a high-stakes effort to fund the government by the end of September, one that was complicated by the GOP's bill to rescind public media and foreign aid funding. Even though Collins voted against the bill, as the chief GOP negotiator she still has to deal with the fallout as Democrats warn the measure poisoned the well and left them with little incentive to work with Republicans. The Maine Republican appears to have the train on the bipartisan tracks — for now. The Senate is hopeful to pass a three-bill appropriations package — known as a 'minibus' — to fund the Departments of Agriculture, Veterans Affairs, Commerce and Justice by the end of the work period, but lawmakers readily acknowledge that this is a high-wire act. 'She's got a tough job,' said Sen. Shelley Moore Capito ( an appropriator. 'I think it's really tough. The whole Congress is fractured on spending.' 'Nobody wants that job right now. … It's not Robert Byrd's Appropriations Committee,' Capito continued, referring to the powerful former West Virginia Democrat who served three stints atop the panel. Amid all of it, Collins must also eye her looming reelection bid next year in the only remaining GOP seat in a blue state, and one Democrats are anxious to flip. Multiple Senate Republicans indicated to The Hill in recent weeks that they fully expect her to move forward with a campaign. They're also praying that she does as they readily admit the seat is gone if she decides to opt against another term. 'She's the only person that can win,' Thune recently told The Hill while laying out their sales pitch for her to move ahead with a campaign. 'She has a really hard job because she's in a conference composed largely of people who represent states that are very different from hers,' Thune said. 'But I do think there's a compelling argument to chair the Appropriations Committee, get it working again and to me that would be a pretty powerful rationale for running.' Polls show a muddled picture for the five-term moderate. A recent survey taken by Morning Consult shows her favorability at only 38 percent, with 54 percent disapproving of her performance — a 16-point difference. However, Maine-based Pan Atlantic Research unveiled a poll last month showing that her favorability remains above water. Despite the tumult and uncertainty, Collins maintained that she doesn't feel the walls closing in on her. 'I've been here a number of years. I've been through many high-pressure events,' Collins told The Hill. 'That's the nature of the job if you're in a leadership position or if you're representing your constituents.' Collins is in a strong fundraising spot, having raked in $2.4 million between April and June. She also has $5.2 million on hand. Perhaps more notable at this point is that Democrats continue to struggle to find a candidate who is willing to take her on. The party is largely pinning their hopes on Maine Gov. Janet Mills (D), 77, taking the plunge, but she has shown few signs of being gung-ho about challenging Collins. Rep. Jared Golden (D-Maine), a former Collins staffer, also declined to take her on and is expected to seek reelection to the House next year instead. Democrats are also still licking their wounds from 2020 when Collins trailed Sara Gideon for much of the cycle after being outspent heavily, only to end up winning by 9 percentage points. Notably Trump, who has made clear his dissatisfaction with those who've opposed his agenda, hasn't trained his fire on the Maine senator. Collins, meanwhile, is making clear she doesn't need any help from the White House. 'I've never had his endorsement and I've never sought it,' she recently told Semafor. 'And I run my own race.' In the meantime, Democrats are hoping to tether Collins to the GOP's 'big, beautiful bill' and the bill to claw back funding, even though she opposed both measures. They specifically point to her vote to open debate on the bill days before she voted against final passage due to the law's impact on Medicaid beneficiaries and rural hospitals in the Pine Tree State. 'Susan Collins is facing record low approval ratings in Maine because when push comes to shove, she will always have the backs of Donald Trump and Washington Republicans, not Mainers,' said Tommy Garcia, a Maine Democratic Party spokesperson. 'In the past month alone, Collins refused to use the power she likes to campaign on to stop devastating cuts to rural broadcast stations and cast a pivotal vote to green light Medicaid cuts.' Even amid the rough-and-tumble stretch, Republicans are maintaining their confidence in her to make it through unscathed. 'She keeps it all together,' said Sen. Kevin Cramer (R-N.D.), likening her to Wonder Woman. 'If you're going to take her on, you better come really well prepared.' 'Even at that,' he continued, 'you're probably not prepared enough.'
Hamilton Spectator
40 minutes ago
- Hamilton Spectator
Audiense Launches MCP Connectors: Bringing Audience Intelligence into your AI Workflow
Fort Worth, TX, July 28, 2025 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE Audiense launches MCP Connectors: Bringing Audience Intelligence into your AI Workflow Fort Worth, TX – July 28, 2025 — Audiense, the leading audience intelligence platform, today unveiled its MCP (Model Context Protocol) connectors – seamless integrations that bring audience insights directly into AI tools like Claude and ChatGPT. This marks a major leap forward in how marketing, research, and strategy teams work with audience insights – making them accessible, actionable, and customizable, without a single line of code. Bringing Audience Intelligence into the AI Ecosystem The new MCP connectors act as real-time bridges between all Audiense consumer intelligence products (including Insights, SOPRISM, Demand, and Tweet Binder) and today's leading generative AI platforms. Instead of pulling data manually or scanning through insights, users can interact with audience data directly within the AI tools they're already using and generate outputs like: All using simple prompts, bringing audience intelligence into their everyday workflows, instantly and intuitively. 'AI isn't just a productivity hack; it's becoming the new interface for how brands engage with their audiences. With MCP, we're embedding Audiense insights directly into that workflow, empowering users to interact with their audience segments in real-time, uncover deeper understanding, and shape strategy without friction. It's not just about working faster, it's about building smarter, more dynamic conversations with the people that matter most.' - Jim Swift, CEO of Audiense Built For How You Work Whether you're shaping strategy or executing creative, Audiense's MCP connectors are designed to support the way modern teams operate, helping them move faster, think deeper, and create better. For Marketers: Build campaign strategies, messaging frameworks, and creative briefs on the fly. For Analysts: Compare audience segments, spot trends, and test hypotheses without touching code. For Strategists: Uncover white space, surface opportunities, and turn audience insight into competitive advantage. For Content & Creative Teams: Generate content calendars, brainstorm ideas, and adapt tone of voice to each persona. 'This isn't just about saving time. It's about possibility. Whether you're writing a brief, testing a hypothesis, or developing an agent, MCP connectors give you a faster, more flexible way to turn insight into action.' - Javier Burón, Product Strategist at Audiense Rethinking How You Work with Insights MCP connectors are designed for speed, flexibility, and real-world applications – redefining how teams interact with insights and deliver outcomes. What sets MCP apart: This launch reaffirms Audiense's commitment to innovation and to building the future of audience intelligence alongside the evolution of AI. To learn more about the MCP connectors, read our latest blog or request a demo . About Audiense Audiense is an AI-powered suite of solutions that helps brands transform complex customer data into meaningful insights and measurable outcomes. Backed by PSG Equity, Audiense combines capabilities from location intelligence, ecommerce analytics, and real-time audience insights to deliver a holistic view of customer behavior, motivation, and intent. Built for strategy, marketing, and growth teams, Audiense empowers brands to engage the right people online and in person, and to personalize every interaction with clarity and precision. Media Contact: Saman Bhatti VP, Growth saman@
Hamilton Spectator
40 minutes ago
- Hamilton Spectator
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company's proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of HCC. HCC is the most common type of primary liver cancer, with GPC3 expressed in over 75% of cases1. ZW251 is a potential first-in-class ADC engineered to selectively target GPC3. It is composed of a humanized IgG1 antibody conjugated to a novel camptothecin-based TOPO1i using a validated peptide cleavable linker. A drug-antibody-ratio (DAR) of four was selected for ZW251 as a lower DAR potentially could unlock a broader range of dose levels, a potential benefit as HCC patients are commonly challenged by impairment of liver function as a result of chronic liver disease and cirrhosis. In preclinical studies, ZW251 demonstrated strong activity in a range of HCC models, including a range of patient derived xenografts exhibiting a breadth of GPC3 expression and noteworthy tolerability in non-human primate toxicology studies at doses up to 120 mg/kg. 'This advancement marks the second ADC from our wholly-owned pipeline, utilizing our proprietary TOPO1i payload, to progress into clinical development, reinforcing confidence in our approach,' said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. 'Like ZW191, which is currently in clinical trials, ZW251 utilizes the same payload paired with an optimized antibody. Our observations with ZW191 in the clinic to date provide a strong foundation as we initiate clinical development of this second ADC. With its novel design, unique mechanism of action, and promising preclinical activity, ZW251 offers the potential to meaningfully improve upon the current standard of care for HCC either as a monotherapy or in combination.' We plan to commence Phase 1 clinical studies for ZW251 in 2025. About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval and China' s NMPA granted conditional approval for zanidatamab to treat adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The European Commission (EC) has granted conditional marketing authorization for Ziihera® as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer previously treated with at least one prior line of systemic therapy. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the U.S., Europe, and China. In addition, zanidatamab is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking Statements This press release includes 'forward-looking statements' or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the efficacy and safety of zanidatamab and Zymeworks' product candidates; ongoing clinical studies and regulatory reviews; the potential addressable market of zanidatamab and Zymeworks' product candidates; the timing of and results of interactions with regulators; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies, clinical trials and the related data; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' product candidates; and the commercial potential of technology platforms and product candidates. When used herein, words such as 'plan', 'believe', 'expect', 'may', 'anticipate', 'potential', 'will', 'intend', 'continues', 'progress', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials, including any required confirmatory trials, may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; conditional regulatory approval may be withdrawn or revoked if any of Zymeworks' or its partners' product candidates fail to satisfy the requirements of any such conditional regulatory approvals; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab and Zymeworks' product candidates may not be successfully commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under 'Risk Factors' in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at and ). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Contacts: Investor Inquiries: Shrinal Inamdar Senior Director, Investor Relations (604) 678-1388 ir@ Media Inquiries: Diana Papove Senior Director, Corporate Communications (604) 678-1388 media@ _______________________ 1 Wang HL et al., Arch Pathol Lab Med 2008.
